Close Menu

lymphoma

The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software. 

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

The company said it plans to use the proceeds raised in the private placement primarily to fund its Hodgkin's lymphoma test clinical trial.

In Science this week: two proteins may help treat muscular dystrophy, and more.

Chromosomes

The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.

Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.

Using a mass spec-based proteogenomic approach, the researchers identified commonalities in neoantigen presentation across mantle cell lymphoma patients.

MLL will be the first European user of Illumina's new high-throughput sequencing platform, the NovaSeq. 

In PNAS this week: common, not rare ERAP1 variants linked to ankylosing spondylitis, recurrent VAV1 mutations in peripheral T-cell lymphoma, and more.

Roche has licensed and plans to commercialize the circulating tumor DNA technology, which the Stanford researchers dubbed CAPP-seq.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.